Mirum Pharmaceuticals (MIRM) Other Non-Current Liabilities (2019 - 2026)

Mirum Pharmaceuticals' Other Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $48.3 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 247.17% year-over-year to $48.3 million; the TTM figure through Mar 2026 stood at $48.3 million (up 247.17% YoY), while the FY2024 annual figure was $2.5 million, down 34.81% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $48.3 million, up from $16.0 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $138.0 million in Q3 2022, with the low at $1.1 million in Q1 2023.
• The 5-year median for Other Non-Current Liabilities is $4.4 million (2022), against an average of $27.6 million.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities soared 726305.26% in 2022, then sank 99.18% in 2023.
• Mirum Pharmaceuticals' Other Non-Current Liabilities stood at $4.5 million in 2022, then slipped by 15.07% to $3.8 million in 2023, then slumped by 34.81% to $2.5 million in 2024, then soared by 536.95% to $16.0 million in 2025, then surged by 201.96% to $48.3 million in 2026.
• Business Quant data shows MIRM's Other Non-Current Liabilities at $48.3 million in Q1 2026, $16.0 million in Q3 2025, and $9.1 million in Q2 2025.